Novo Nordisk has started building its first brand-new manufacturing facility in Denmark since the millennium, saying it plans ...

Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to ...

In a time when pharmaceutical companies no longer have the economic luxury of decades-long development cycles, indication ...

The analysis found that across all the 339 appraisals carried out for the new medicines, the median gain in quality-adjusted ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a ...

Essentially, what Concr demonstrates is that training their algorithms on smaller, yet more diverse, data can lead to increased accuracy, due to the broader biological variability within that training ...

Investors seemed to panic after the announcement, with a sell-off driving Keros' share price down 73%, reversing strong gains ...

Private equity group Carlyle has joined forces with other investors on a €900 million-plus recapitalisation of UK drugmaker ...

A new study has confirmed that the rate of colorectal cancer is rising in younger adults around the world, with England among ...

The Institute for Clinical and Economic Review (ICER) has published its annual report on "unsupported" price increases for medicines that it says have added around $815 million to US drug spending.

AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...

Editas ended the third quarter with cash reserves of around $256 million, down from $318 million three months earlier. It said at the time that was enough to fund operations to the middle of 2026, but ...